Trial · NCT02927314
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Efficacy of CF102 as determined by change in serum alanine aminotransferase (ALT) levels | 12 weeks | Mean percent change in serum alanine aminotransferase (ALT) levels |
| Primary | Efficacy of CF102 as determined by change in magnetic resonance imaging-determined hepatic steatosis | 12 weeks | Percent change from Baseline in hepatic steatosis measured by magnetic resonance imaging-determined proton-density fat-fraction (MRI-PDFF) |
| Secondary | Body weight in subjects with NAFLD | 12 weeks | Change from baseline in body weight (kg) |
| Secondary | Waist circumference in subjects with NAFLD | 12 weeks | Change from baseline in waist circumference (cm) |
| Secondary | HDL cholesterol levels in subjects with NAFLD | 12 weeks | Change from baseline in serum triglyceride and HDL cholesterol levels (mg/dL) |
| Secondary | Normalization of serum ALT levels in subjects with NAFLD | 12 weeks | Proportion of all subjects whose serum ALT level normalizes |
| Secondary | Serum aspartate aminotransaminase (AST) levels in subjects with NAFLD | 12 weeks | Change from baseline in serum AST levels |
| Secondary | Hemoglobin A1c levels and degree of insulin resistance | 12 weeks | Change from baseline in Homeostasis Model Assessment (HOMA) |
| Secondary | Pharmacokinetics (PK) of CF102 in this population | 12 weeks | PK of CF102 will be assessed through steady state trough drug level |
| Secondary | Peripheral blood expression of the A3 adenosine receptor (A3AR). | 12 weeks | Change from baseline in A3 adenosine receptor (A3AR) expression level |
| Secondary | Nature, frequency, and severity of adverse events in this patient population | 12 weeks | Nature, frequency, and severity (by CTCAE or comparable scale) of adverse events |
| Other | Serum adiponectin levels | 12 weeks | Change from baseline in serum adiponectin levels in subjects with NAFLD |
| Other | Serum leptin levels | 12 weeks | Change from baseline in serum leptin levels in subjects with NAFLD |
| Other | Serum alpha-2 macroglobulin levels | 12 weeks | Change from baseline in serum alpha-2 macroglobulin levels in subjects with NAFLD |
| Other | Serum apolipoprotein A1 levels | 12 weeks | Change from baseline in serum apolipoprotein A1 levels in subjects with NAFLD |
| Other | Serum haptoglobin levels | 12 weeks | Change from baseline in serum haptoglobin levels in subjects with NAFLD |
| Other | Serum C-reactive protein levels | 12 weeks | Change from baseline in serum C-reactive protein levels in subjects with NAFLD |
| Other | Liver stiffness | 12 weeks | Change from baseline in liver stiffness by FibroScan in subjects with NAFLD |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02927314/registered